On February 13, 2008, Theratechnologies Inc. announced that it had successfully completed its recently announced public offering of 3,500,000 common shares at a price of $8.50 per share for gross proceeds of $29,750,000. The offering was made through a syndicate of underwriters led by BMO Capital Markets, including Canaccord Capital, National Bank Financial, Desjardins Securities and Jennings Capital. Theratechnologies has also granted to the underwriters an over-allotment option to purchase an additional 350,000 common shares at the same price, exercisable by the underwriters for a period of 30 days from closing. The net proceeds of the offering will be used by Theratechnologies primarily to finance the continuing development of tesamorelin, to finance part of its commercialization efforts, and for working capital purposes. The common shares were offered by way of a prospectus supplement under Theratechnologies' short form base shelf prospectus allowing for an issuance of common shares of up to $35 million. Theratechnologies was advised by a team from Fasken Martineau comprised of Robert Girard, Catherine Isabelle, Jean Michel Lapierre and Rebecca McLeod.